ArticleJournal of the International Association of Providers of AIDS Care
Tuberculosis Treatment Uptake and Outcomes Among HIV-Positive Patients on Antiretroviral Therapy at a Tertiary Health Facility in South-South, Nigeria.
Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThere is a significant intersection between Tuberculosis (TB) and HIV, which has contributed greatly to the disease burden, especially in Nigeria. Among approximately 1.9 million people living with HIV (PLHIV), an estimated 46,000 also had TB in 2019 alone. HIV-associated TB incidence has continuously increased nationally. It is important to understand how PLHIV with TB undergo treatment because this is essential for improving outcomes. This study assessed the uptake of TB treatment and evaluated outcomes among PLHIV receiving antiretroviral therapy at a tertiary healthcare facility in South-South Nigeria.MethodsThe study was a hospital-based retrospective cohort study, that reviewed the records of 213 PLHIV treated for TB between January 2015 and December 2019. Patient records were examined and data extracted using a structured pro forma. Analysis was done with IBM SPSS version 26 using descriptive statistics (frequencies and Percentages) and inferential statistics (chi-square test) with statistical significance set at p < 0.05.ResultsAll participants were enrolled in the National Tuberculosis, Leprosy and Buruli Ulcer Control Programme (NTBLCP). Of these, 182 individuals (85.5%) successfully completed the full 24-week course of anti-tuberculosis therapy. Treatment outcomes were classified separately, with 99 (46.5%) patients cured and 74 (34.7%) completing treatment without bacteriological confirmation, 28 (13.1%) discontinued treatment prematurely, and 12 (5.6%) were referred to other healthcare facilities for continued care.ConclusionTB treatment outcomes among PLHIV were suboptimal, with notable levels of default and transfer-out. Outcomes were significantly associated with socio-demographic factors and treatment duration. Strengthening adherence, support mechanisms and improving access to affordable diagnostic monitoring services may enhance TB treatment outcomes among PLHIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.